/

Codexis, Inc.

CDXS US

CDXS USCodexis, Inc.

United States Composite

2.83

USD

+0.03

(+1.07%)

-1.12EPS Dil.

-2.53P/E

197.83MMarket Cap

Next Earnings

May 2

Held by Insiders

3.22%

Held by Institutions

82.75%

Short % of Float

3.62%

YTD Yield

-18.78%

3Y Yield

-85.45%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

195

132

213

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

120

103

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

11.79%

9.57%

-49.64%

Net Income, GAAP

-28.64%

-56.41%

-123.53%

Free Cash Flow

-NaN%

-433.97%

-2,000.00%

Total Cash Common Dividend

- -

Total Equity

18.46%

18.91%

-40.00%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

105

2022

139

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.14

-0.07

0.03

-0.16

-0.33

2022

-0.13

-0.04

-0.15

-0.19

-0.51

2023

-0.34

-0.17

-0.50

-0.10

-1.12

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Dr. Stephen George Dilly MBBS, Ph.D.
Full Time Employees: 174
Sector: Healthcare
Industry: Biotechnology
Address: 200 Penobscot Drive Redwood City CA United States 94063
Website: www.codexis.com
Business: Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Company News

Yahoo
9 days ago
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Yahoo
21 days ago
Favourable Signals For Codexis: Numerous Insiders Acquired Stock

Company Description

CEO: Dr. Stephen George Dilly MBBS, Ph.D.
Full Time Employees: 174
Sector: Healthcare
Industry: Biotechnology
Address: 200 Penobscot Drive Redwood City CA United States 94063
Website: www.codexis.com
Business: Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.